Amicus Therapeutics Rockets Ahead with Stellar 32% Revenue Surge: What’s Next?
Amicus Therapeutics achieved a 32% increase in total revenue for 2024, totaling $528 million, primarily driven by Galafold’s 18% growth to $458 million. New products POMBILITI and OPFOLDA generated $70 million, marking a strong entry into the market for late-onset Pompe disease
